0
Your cart

Your cart is empty

Books > Medicine > Other branches of medicine > Pharmacology

Buy Now

Selective COX-2 Inhibitors - Pharmacology, Clinical Effects and Therapeutic Potential (Paperback, Softcover reprint of the original 1st ed. 1998) Loot Price: R2,753
Discovery Miles 27 530
Selective COX-2 Inhibitors - Pharmacology, Clinical Effects and Therapeutic Potential (Paperback, Softcover reprint of the...

Selective COX-2 Inhibitors - Pharmacology, Clinical Effects and Therapeutic Potential (Paperback, Softcover reprint of the original 1st ed. 1998)

Sir John R. Vane, Jack H. Botting

 (sign in to rate)
Loot Price R2,753 Discovery Miles 27 530 | Repayment Terms: R258 pm x 12*

Bookmark and Share

Expected to ship within 10 - 15 working days

Donate to Against Period Poverty

The mainstay of therapy for rheumatoid disease is the non-steroid antiinflammatory drugs (NSAIDs), despite their inherent gastrointestinal toxicity and ability to cause renal damage in susceptible patients. The theory that the beneficial and toxic effects of NSAIDs stem from a reduction in prostanoid production through inhibition of cyclooxygenase implied that particular toxicities were inevitable with NSAIDs and would always be correlated with efficacy. However, over the years, it became apparent that at therapeutic doses, some NSAIDs had greater toxic side-effects than others, a fact not explained by the general theory. A significant clarification arose from the discovery that there are two distinct isoforms of COX, a constitutive enzyme (COX-I) responsible for the production of prostanoids necessary for platelet aggregation and protection of the gastric mucosa and kidney; and an inducible enzyme (COX-2) that is newly synthesized at sites of tissue damage and produces prostaglandins that manifest pathological effects. It became clear that different NSAIDs had greater or lesser effects on COX-I when used in therapeutic doses, explaining the variation in side-effects. ' The elucidation of the crystal structure of these different enzymes and the skills of medicinal chemists have led to the synthesis of new chemicals with a selectivity for the inducible enzyme, and thus with therapeutic efficacy without those toxic effects result ing from inhibition of the constitutive enzyme.

General

Imprint: Springer
Country of origin: Netherlands
Release date: November 2012
First published: 1998
Editors: Sir John R. Vane • Jack H. Botting
Dimensions: 240 x 160 x 9mm (L x W x T)
Format: Paperback
Pages: 150
Edition: Softcover reprint of the original 1st ed. 1998
ISBN-13: 978-9401060417
Categories: Books > Medicine > Other branches of medicine > Pharmacology > General
LSN: 940106041X
Barcode: 9789401060417

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners